TAK-778 is a derivative of ipriflavone that has been shown to induce bone growth in both in vitro and in vivo models; it increases the area of mineralized nodules with continuous treatment (10 μM for 1–21 days); significantly stimulates cellular alkaline phosphatase (ALP) activity at concentrations of 1 μM and higher; slightly but significantly increases cellular DNA content at confluence; induces dose-dependent increases in soluble collagen and osteocalcin secretion into the culture medium from days 5 to 7; enhances the secretion of both TGF-β and IGF-I throughout the 21-day culture period; increases saturated cell density in a dose-dependent manner (though 10 μM significantly reduces it); promotes dose-dependent increases in radio-opaque area formation in bone defects following a single local application of TAK-778/PLGA-MC (0.2–5 mg/site); facilitates radiological osseous union across defects two months post-operation; and causes a pronounced increase in lumbar vertebral bone mineral density (BMD) in ovariectomized (OVX) rats upon oral administration compared to vehicle controls.